The “little pink pill,” Addyi, has been approved by the Food and Drug Administration (FDA) for use by postmenopausal women, making it the first medication available for low sexual desire in both pre- and postmenopausal women under 65. This development significantly increases accessibility for women experiencing hypoactive sexual desire disorder (HSDD).
Addyi targets HSDD, which is characterized by a chronically low sex drive that causes distress. This condition affects about one in 10 women, making it a common sexual health issue. The medication is taken once daily at bedtime, and many women find it enhances their intimate lives.
Jessica Shepherd, MD, emphasizes the importance of this advancement in women’s sexual health. However, Addyi may not be effective for everyone, as libido is influenced by multiple factors. According to Lauren Streicher, MD, the medication works by affecting serotonin levels in the brain but does not address all aspects of libido.
Initially approved in 2015 for premenopausal women, the recent FDA decision to include postmenopausal women was based on the same clinical data. Trials showed that Addyi improved sexual desire scores more effectively than a placebo, with a meaningful benefit reported by many women.
The FDA’s Priority Review designation expedited the approval process, making Addyi the only treatment of its kind for postmenopausal women. While men have various options for low libido, Addyi is one of the few FDA-approved medications for women. Dr. Shepherd and Jennifer Wider, MD, highlight the significance of this option for empowering women in their sexual health.
Addyi is particularly beneficial for postmenopausal women due to hormonal changes during menopause, such as declines in estrogen, progesterone, and testosterone. Dr. Shepherd notes that Addyi can help restore sexual desire and improve libido without relying solely on hormone replacement therapy.
Dr. Streicher advises viewing Addyi as an additional tool rather than a cure-all. It offers a safe option for addressing sexual health issues, though it may not fully resolve them.
For those considering Addyi, consulting a healthcare provider is essential. They can provide guidance on whether this medication is suitable based on individual needs and circumstances.